Benralizumab Phase 3 Trial
The correction concerns a randomized, placebo-controlled phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome. The correction concerns a randomized, placebo-controlled phase 3 trial of benralizumab versus placeb…
1 sources - 5 claims
The correction concerns a randomized, placebo-controlled phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome. The correction concerns a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome.